A selloff in U.S. stocks picked up steam late Friday morning, following a volatile trading session in Asian markets that ended with the Shanghai Composite down more than 5%.
The Dow Jones industrial average (INDU) fell 85 points, or 0.8%, and the S&P 500 (SPX) lost 13 points, or 1%. The tech-heavy Nasdaq (COMP) decreased 27 points, or 1%.
G-20 leaders finished up their meeting in Seoul, South Korea, without any comprehensive plan to combat global economic woes. But they did agree to address "persistently large imbalances" next year.
Friday, November 12, 2010
Some Average Investors May Be Shut Out of GM's IPO
Just two years after a taxpayer bailout salvaged General Motors, some of the nation’s largest retail brokerage firms are apparently being shut out of what is poised to be a lucrative investment opportunity as the auto company goes public.
Charles Schwab [SCHW 15.02 -0.09 (-0.6%) ], TD Ameritrade, and E*Trade are not accepting client orders for GM shares at the moment because they do not expect to receive stock allocations when the company goes public next week, according to investors and brokerage-firm employees.
Charles Schwab [SCHW 15.02 -0.09 (-0.6%) ], TD Ameritrade, and E*Trade are not accepting client orders for GM shares at the moment because they do not expect to receive stock allocations when the company goes public next week, according to investors and brokerage-firm employees.
Old DSE server bars market surveillance
Stock-market-surveillance activity is being hampered as updating of the Dhaka Stock Exchange server is not yet complete, leaving the chances of bamboozling the market regulators.
Sources said it makes Security Exchange Commission (SEC) unable to conduct the real-time surveillance on the bourse operations off and on.
As the surveillance department does not get real-time data, it works with the backdated data of 15 minutes to one hour. “The SEC also cannot act against those who are violating the rules, as it is not getting the instant data,” said a competent source.
Sources said it makes Security Exchange Commission (SEC) unable to conduct the real-time surveillance on the bourse operations off and on.
As the surveillance department does not get real-time data, it works with the backdated data of 15 minutes to one hour. “The SEC also cannot act against those who are violating the rules, as it is not getting the instant data,” said a competent source.
Friday, November 5, 2010
The Fresh Market Announces Pricing of Its Initial Public Offering
The Fresh Market announced today the pricing of its initial public offering of its common stock at $22.00 per share. The offering will consist of 13,175,000 shares to be sold by stockholders of The Fresh Market. The underwriters have a 30-day option to purchase up to an additional 1,976,250 shares of common stock from the selling stockholders at the public offering price, less the underwriting discount.
The Fresh Market common stock will begin trading on The NASDAQ Global Select Market on November 5, 2010 under the symbol "TFM".
BofA Merrill Lynch, J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.
The Fresh Market common stock will begin trading on The NASDAQ Global Select Market on November 5, 2010 under the symbol "TFM".
BofA Merrill Lynch, J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.
Dale Jarrett Racing Adventure CEO Featured Interview with StockGoodies Radio
HICKORY, N.C., Nov. 5, 2010 /PRNewswire via COMTEX/ -- Dale Jarrett Racing Adventure, Inc. /quotes/comstock/11k!djrt (DJRT 0.05, +0.01, +14.16%) , a "Full Throttle" lifetime experience company, announced today that CEO Tim Shannon will be the featured guest interview on the fastest growing Stock Trading community, StockGoodies.com Radio. The interview will be held on Monday, November 8th at 8:00 p.m. EST.
The interview can be heard at http://www.blogtalkradio.com/stockgoodies. The archived version can be found on the homepage of www.StockGoodies.com.
About Stock Goodies:
The interview can be heard at http://www.blogtalkradio.com/stockgoodies. The archived version can be found on the homepage of www.StockGoodies.com.
About Stock Goodies:
Fitch Affirms USG's IDR at 'B' & Rates $350MM Sr. Unsecured Offering 'BB/RR1'; Outlook to Negative
CHICAGO, Nov 05, 2010 (BUSINESS WIRE) -- Fitch Ratings has affirmed the ratings of USG Corporation /quotes/comstock/13*!usg/quotes/nls/usg (USG 14.91, +0.71, +5.00%) as follows:
--Issuer Default Rating (IDR) at 'B';
--Secured bank credit facility at 'BB/RR1';
--Senior unsecured guaranteed notes at 'BB/RR1'.
Fitch has also assigned a 'BB/RR1'rating to USG's private offering of $350 million of senior unsecured notes. The new issue will be guaranteed on a senior unsecured basis by certain of USG's domestic subsidiaries.
--Issuer Default Rating (IDR) at 'B';
--Secured bank credit facility at 'BB/RR1';
--Senior unsecured guaranteed notes at 'BB/RR1'.
Fitch has also assigned a 'BB/RR1'rating to USG's private offering of $350 million of senior unsecured notes. The new issue will be guaranteed on a senior unsecured basis by certain of USG's domestic subsidiaries.
Research and Markets: Dental Laboratories Industry in the U.S. and Its International Trade - the Updated Q3 2010 Edition
DUBLIN -- Research and Markets has announced the addition of Supplier Relations US, LLC's new report "Dental Laboratories Industry in the U.S. and its International Trade [Q3 2010 Edition]" to their offering.
This U.S. industry comprises establishments primarily engaged in manufacturing dentures, crowns, bridges, and orthodontic appliances customized for individual application. This 6-digit NAICS industry (339116) is under the hierarchy of Medical Equipment and Supplies Manufacturing Industry (33911), Miscellaneous Manufacturing Subsector (339), and the Manufacturing Sector (31-33). Its SIC equivalent code is: 8072 - Dental Laboratories.
This U.S. industry comprises establishments primarily engaged in manufacturing dentures, crowns, bridges, and orthodontic appliances customized for individual application. This 6-digit NAICS industry (339116) is under the hierarchy of Medical Equipment and Supplies Manufacturing Industry (33911), Miscellaneous Manufacturing Subsector (339), and the Manufacturing Sector (31-33). Its SIC equivalent code is: 8072 - Dental Laboratories.
Global X Funds Adds Uranium ETF to its Cleantech Fund Suite
NEW YORK, Nov. 5, 2010 -- /PRNewswire/ -- Global X Funds, the New York based provider of exchange traded funds, launched today the Global X Uranium ETF (Ticker: URA). The launch is the latest expansion in the ETF issuer's cleantech commodity funds.
Uranium is seen as the clean resource alternative for electric generation. One pound of uranium can generate as much energy as 20,000 pounds of coal, and leaves behind a fraction of the carbon footprint. Almost all the uranium mined today is used to produce electricity, and that provides about 16% of the world's electricity. Since the bull market for uranium in 2006-2007, many new nuclear plant development projects have been initiated around the world. However, uranium supply is forecasted to be in deficit for every year from 2010 onward. RBC Capital Markets estimates that the price of uranium will peak at $80/lb within three years.
Uranium is seen as the clean resource alternative for electric generation. One pound of uranium can generate as much energy as 20,000 pounds of coal, and leaves behind a fraction of the carbon footprint. Almost all the uranium mined today is used to produce electricity, and that provides about 16% of the world's electricity. Since the bull market for uranium in 2006-2007, many new nuclear plant development projects have been initiated around the world. However, uranium supply is forecasted to be in deficit for every year from 2010 onward. RBC Capital Markets estimates that the price of uranium will peak at $80/lb within three years.
Fannie Mae Prices New Issue 2-Year Benchmark Notes® due December 28, 2012
WASHINGTON, Nov. 5, 2010 -- /PRNewswire/ -- The following is being issued by Fannie Mae (OTC Bulletin Board: FNMA):
2-Year
Pricing Date November 5, 2010
Settlement Date November 9, 2010
Maturity Date December 28, 2012
Issue Size $7.5 billion
Coupon 0.375%
Price 99.837
Yield 0.452%
Payment Dates Each December 28th and June 28th, beginning December 28, 2010
Spread +10.5 basis points / 0.375% 10/31/12 U.S. Treasury
CUSIP 31398A6F4
Listing Application will be made to list the securities on the EuroMTF market of the Luxembourg Stock Exchange
Barclays Capital Inc., Deutsche Bank Securities Inc., and UBS Securities LLC are the joint lead managers. The co-managers include, BNP Paribas Securities Corp., Cabrera Capital Markets LLC, Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC,
2-Year
Pricing Date November 5, 2010
Settlement Date November 9, 2010
Maturity Date December 28, 2012
Issue Size $7.5 billion
Coupon 0.375%
Price 99.837
Yield 0.452%
Payment Dates Each December 28th and June 28th, beginning December 28, 2010
Spread +10.5 basis points / 0.375% 10/31/12 U.S. Treasury
CUSIP 31398A6F4
Listing Application will be made to list the securities on the EuroMTF market of the Luxembourg Stock Exchange
Barclays Capital Inc., Deutsche Bank Securities Inc., and UBS Securities LLC are the joint lead managers. The co-managers include, BNP Paribas Securities Corp., Cabrera Capital Markets LLC, Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC,
GenVec Announces Listing Transfer to the Nasdaq Capital Market
GAITHERSBURG, Md., Nov. 5, 2010 -- /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that NASDAQ has approved its application to transfer its stock listing to The Nasdaq Capital Market (the "Capital Market") from The Nasdaq Global Market, effective at the opening of business on Monday, November 8, 2010. The company's common stock will continue to be traded under the symbol "GNVC". The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as the Nasdaq Global Market.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines.
Subscribe to:
Posts (Atom)